Clinic Valuation Guide 2026: How to Price Your Practice

TL;DR. Outpatient clinic valuations in 2026 run on adjusted EBITDA multiples, not revenue multiples or net income. Multiples typically range from 4-7x for primary care add-ons to 12-15x for dermatology platforms, and adjusted EBITDA is usually 30-50% higher than what owners calculate themselves once personal expenses and owner comp are normalized. Most owners underprice their practice because they apply the wrong multiple to the wrong number.

"I think it's worth about a million"

That is roughly what a clinic owner told me last month, sitting across the table from a PE-backed platform that had been circling for six months. The practice did $3.4M in revenue. He had an offer for $4.6M on the table. He thought he was being lowballed because his accountant had said the practice was worth "about a million."

His accountant was using a 0.3x revenue rule of thumb that has not been the standard valuation methodology for outpatient clinics in over a decade. The buyer was using a 7x adjusted EBITDA multiple that is the actual current market for a practice his size. The gap between those two methods, on his specific numbers, was $3.6M. The accountant was wrong by a factor of nearly five.

This is not unusual. Most clinic owners I talk to either have never had a serious valuation done, or had one done years ago using a methodology that does not apply to today's market. They either accept low offers because they think their practice is worth less than it is, or reject reasonable offers because they think it is worth more. Both errors cost real money.

Here is how valuation actually works in 2026, with the four methodologies sophisticated buyers use, and where most owners get it wrong.

The four valuation methods (and which one matters)

There are four standard approaches to valuing a medical practice. They produce dramatically different numbers because they measure different things.

1. Asset-based valuation. Adds up the tangible assets (equipment, leasehold improvements, AR, supplies) and subtracts liabilities. A floor value, useful only for liquidation scenarios or asset-heavy practices. For a typical outpatient clinic, this captures maybe 5-15% of actual transaction value.

2. Revenue multiples. Practice value as a multiple of trailing twelve-month revenue. This was dominant twenty years ago and still used as a quick sanity check. Dangerous as a decision basis, because two practices with identical revenue can produce very different EBITDA depending on staffing efficiency, payer mix, and overhead.

3. EBITDA multiples (the current standard). Practice value as a multiple of adjusted earnings before interest, taxes, depreciation, and amortization. This is what every PE buyer, DSO, MSO, hospital system, and sophisticated strategic acquirer uses for outpatient practices in 2026. Multiples range from 4-7x for primary care to 6-12x for specialty care, with platform deals running 3-5 turns higher than add-ons (per FOCUS Investment Banking's 2026 multiples dashboard).

4. Income approach (discounted cash flow). Projects future cash flows and discounts them to present value. Most accurate in theory but rarely used as the primary method in real transactions. Used as a confirming methodology alongside EBITDA multiples, typically receiving 20-30% weighting in institutional valuations.

EBITDA multiples drive 70-80% of the value conclusion in any transaction over $2M. If your accountant is quoting you a number based on revenue multiples or asset value, they are using the wrong tool. Same with Seller's Discretionary Earnings (SDE), which is appropriate for practices under $2M where the buyer is a single practitioner, but irrelevant once you are talking to PE platforms or hospital systems.

Why owner-calculated EBITDA is almost always wrong

Here is where most owners leave the most money on the table.

The number on your P&L labeled "net income" is not your EBITDA. The EBITDA you would use as a starting point (net income plus interest, taxes, depreciation, amortization) is not adjusted EBITDA. And adjusted EBITDA is what the buyer is paying for.

Adjusted EBITDA is your EBITDA after a series of normalization adjustments that strip out non-recurring items, owner-specific spending, and below-market arrangements that a new owner would not inherit. Done correctly, this number is often 40-80% higher than what the owner has been quoting themselves.

The most common adjustments that move the number up:

Owner compensation above market. If you are paying yourself $450K in W-2 plus $200K in distributions plus benefits, but the market rate for a physician in your specialty is $350K all-in, that $300K gap is an EBITDA add-back. A new owner would only need to pay $350K to fill your clinical role.

Personal expenses run through the practice. Car leases, country club memberships, family cell phone plans, home office deductions on homes you barely work from, travel that is more leisure than business. These are legitimate tax deductions. They are also EBITDA add-backs in a valuation. We routinely find $50K-$200K of personal expenses flowing through clinic books that the owner has never thought of as practice cost.

One-time expenses. Lawsuit settlements, equipment replacement that will not recur, an office move, a software implementation. None of these belong in your normalized run-rate EBITDA.

Family on payroll. Your spouse who handles "marketing" but does not actually work full-time. Your son who works summers at $40K. These come off the cost base in normalization.

Below-market provider compensation that gets adjusted up. This works the opposite direction. If you pay an associate $180K to do work the market compensates at $250K, the buyer assumes the gap closes post-deal because the associate will otherwise leave. That $70K comes off your EBITDA.

Below-market rent. If you own the building and charge yourself $4K/month rent on a space that would lease at $9K market, the buyer adjusts rent up. That $60K/year reduces EBITDA. Most owners do not realize this works against them.

The first time we run normalized EBITDA for a clinic owner, the number is usually 30-50% higher than they thought. Some adjustments will not survive due diligence, but the net is almost always meaningfully above where they started.

The 2026 multiples by specialty

Multiples are not constant. They vary by specialty, by practice size, by payer mix, by geography, and by whether you are a platform or an add-on acquisition. Here is what current data shows.

Add-on multiples reflect typical published ranges; platform multiples are derived by applying a 3-5 turn premium per FOCUS Banking and Sofer Advisors framework. Actual deal multiples vary based on size, geography, payer mix, and market conditions.

Sources: FOCUS Investment Banking 2026 dashboard, Sofer Advisors 2025-2026 guide, Physician Growth Partners dermatology and orthopedic reports.

The "platform" column applies to practices that PE wants to use as the foundation for a roll-up, typically with $3M-$10M in EBITDA, multiple locations, strong management, and clean financials. The "add-on" column applies to practices being acquired by an existing platform.

Two things most owners miss.

First, the multiple expands meaningfully as you scale. A $600K EBITDA dermatology practice trades at 7-8x. A $3M EBITDA dermatology practice with the same margins trades at 10-12x. The same dollar of EBITDA is worth 50% more once you cross the platform threshold. This is why holding for an additional 18-24 months and growing through acquisition often produces more value than selling now.

Second, specialty matters more than people realize. Cardiology and ophthalmology trade at meaningfully higher multiples than primary care or PT, even at the same EBITDA. If you have an opportunity to add a higher-multiple service line before sale (cardiology cardiac monitoring, ophthalmology premium IOLs, dermatology cosmetic), the multiple expansion can offset the operating risk.

What a PE buyer actually pays attention to

The multiple is not just a function of specialty and size. Buyers adjust the multiple they offer based on practice quality factors. Here is what moves your multiple up or down by 1-3 turns.

Multiple locations. A single-location practice trades at a discount to a 3-location practice at the same total EBITDA. Buyers see geographic concentration as risk.

Provider concentration. If 50%+ of revenue comes from the selling owner, the multiple drops. Buyers know that revenue is at risk post-sale. A practice where revenue is distributed across 4-6 providers commands a higher multiple than one where the founder produces 70% of the work.

Payer mix. Strong commercial mix (60%+) commands a premium. Heavy Medicaid exposure depresses the multiple. Heavy Medicare exposure depresses it less, but still matters given the long-term reimbursement decline.

Revenue cycle quality. A practice with 95%+ clean claim rate, 28 days in AR, and a demonstrably small gap between billing and collections commands more than a practice with 82% clean claim rate, 45 days in AR, and uncollected balances stacking up.

Growth trajectory. Trailing 12-month revenue growth above 8% adds to the multiple. Flat or declining revenue subtracts.

Clean financials. Location-level P&Ls, provider-level production reports, monthly financial statements going back 24-36 months, organized payer contracts. Having this data organized adds 0.5-1 turn to the multiple. The absence of it can subtract 2 turns or kill the deal entirely.

Real estate. If you own the practice real estate, you have optionality. You can sell the practice and lease back the building (sale-leaseback), or you can sell both together. Buyers typically prefer the sale-leaseback because it does not tie up their capital in real estate.

The four ways owners get the number wrong

After running valuations on hundreds of clinics, four mistakes come up over and over.

Using net income instead of adjusted EBITDA. Net income reflects your tax strategy, not your earning power. A practice that aggressively minimizes taxable income through legitimate strategies looks worse on net income but the same on adjusted EBITDA. Owners who apply a multiple to net income systematically lowball their value by 30-60%.

Forgetting to add back personal expenses. Most owners have not catalogued the personal spending flowing through the practice. When we walk through it, we typically find $80K-$200K of add-backs the owner had forgotten about. At a 7x multiple, $150K of add-backs is over $1M in valuation.

Ignoring the platform vs add-on distinction. A practice valued as a platform deal trades at 3-5 turns higher than the same practice valued as an add-on. If you are at the size threshold (typically $1.5M+ EBITDA, multiple locations, scalable management), reaching platform status can change your sale price by millions.

Selling individually instead of as part of a group. Three independent dermatology practices each doing $800K in EBITDA are worth roughly $5.6M each as add-ons (7x). The same three practices combined into a single $2.4M EBITDA group with shared overhead is worth roughly $26M-$28M as a small platform (11-12x). Owners who sell individually because it is "easier" leave a third or more of the value on the table.

What you should do if you are within 3 years of selling

If you might sell in the next 12-36 months, the work starts now. Even if you decide not to sell, preparing your practice for valuation is the same work that improves your operations.

Get a real valuation done. Not from your accountant unless your accountant specializes in healthcare M&A (most do not). Get a healthcare-specific advisor or fractional CFO to run normalized adjusted EBITDA, apply specialty-appropriate multiples, and give you a defensible value range. Valuation services typically range from $5K to $25K depending on complexity, per industry rates. It is the highest-ROI consulting spend you will make.

Clean up the financials. Move personal expenses out of the business. Normalize owner compensation. Fix your chart of accounts. Produce monthly financial statements with location-level P&Ls. Run provider-level profitability analysis so you can defend provider economics in due diligence.

Build the data room. Last 36 months of monthly financials. Payer contracts with current fee schedules. Provider compensation agreements. Lease agreements. Organizational chart. Quality and patient satisfaction data. Compliance documentation. The buyer will ask for all of this. Having it organized in advance accelerates the deal and demonstrates operational competence.

Diversify revenue. If you produce more than 40% of the practice's revenue yourself, hire or contract additional providers. Moving from "founder produces 60%" to "founder produces 30%" is often worth 1-2 turns of multiple.

Renegotiate commercial contracts. If you have not renegotiated in two years, the trailing 12-month EBITDA going into your sale will be lower than it could be. A 4% commercial rate increase on a $2M commercial book is $80K of EBITDA, worth $560K-$960K at exit multiples.

The full timeline for a 12-18 month exit prep is laid out in selling your practice in 2027. The valuation work described here is the foundation everything else sits on.

The number that matters is not the number you have in your head

The single most expensive mistake a clinic owner can make is assuming they know what their practice is worth without rigorous analysis. Whether you are accepting a low offer because you think your practice is worth less, or rejecting a fair offer because you think it is worth more, the cost is the same: real money you will not get back.

If you want to know what your practice is actually worth using current 2026 multiples and proper EBITDA normalization, take the free assessment. Our fractional CFO services include valuation modeling, EBITDA normalization, and exit prep for owners who want a defensible number before they get the call.